48 articles for HG Selnick
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
27
(E)-Alkenes as replacements of amide bonds: development of novel and potent acyclic CGRP receptor antagonists.
Merck
15
[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.
Merck Research Labortories
8
MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.
Merck Research Laboratories
25
P2 pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold.
Merck Research Laboratories
43
Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors.
Merck Research Laboratories
8
4-Oxospiro[benzopyran-2,4'-piperidines] as class III antiarrhythmic agents. Pharmacological studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-on e (L-691,121).
Merck Research Laboratories
24
Design and synthesis of potent and selective macrocyclic thrombin inhibitors.
Merck Research Laboratories
16
Preparation and evaluation of 1,3-diaminocyclopentane-linked dihydropyrimidinone derivatives as selective alpha1a-receptor antagonists.
Merck Research Laboratories
30
Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
Merck Research Laboratories
12
Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality.
Merck
30
SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition.
Merck Research Laboratories
18
Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility.
Merck
30
Invention of novel 3-aminopiperidin-2-ones as calcitonin gene-related peptide receptor antagonists.
Merck & Co.
25
Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors.
Merck Research Laboratories
14
9-hydroxyazafluorenes and their use in thrombin inhibitors.
Merck Research Laboratories
35
Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group.
Merck Research Laboratories
10
Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics.
Merck Research Laboratories
23
Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position.
Merck Research Laboratories
29
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.
Merck Research Laboratories
41
Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1).
Merck Research Laboratories
7
Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists.
Merck Research Laboratories
16
Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.
Merck
34
In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.
Merck Research Laboratories
34
Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Merck Research Laboratories
49
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.
Merck
18
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide.
Merck Research Laboratories
3
Isoxazolo-quinazolines as modulators of protein kinase activity
Nerviano Medical Sciences
16
2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
Northwestern University
40
Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors
Bayer Intellectual Property
21
Synthesis and characterization of new piperazine-type inhibitors for mitochondrial NADH-ubiquinone oxidoreductase (complex I).
Kyoto University
4
Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
Banyu Pharmaceutical
5
Characterization of the binding site for a novel class of noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists.
Pfizer
22
Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain.
Novo Industri
4
8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors.
UniversitÄT Heidelberg